Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market
Technical Rating:
01- The long term trend is positive and the short term trend is neutral. The long term trend gets the benefit of the doubt for now.
02- OCGN is one of the better performing stocks in the Drugs industry, it outperforms 97% of 721 stocks in the same industry.
03- A new 52 week high is currently being made by OCGN, which is a very good signal! However, this is in line with the S&P500, which is also trading near new highs.
04- In the last month OCGN has a been trading in the 1.40 - 3.50 range, which is quite wide. It is currently trading near the high of this range.
05- OCGN has an average volume of 62182700. This is a good sign as it is always nice to have a liquid stock.
06- Looking at the yearly performance, OCGN did better than 98% of all other stocks. However, this relatively good performance is mostly due to a recent big move.
07- Considerably lower volume is observed in the last couple of days.
-------------------------------------
Statistics:
1 Month : -1.09%
3 Months :546.43%
6 Months : 229.09%
12 Months : 254.42%
-------------------------------------
Setup Analysis:
OCGN has an average technical rating and it also does not offer a high quality setup at the moment. Prices have been extended to the upside lately. For a nice entry it is better to wait for a consolidation.
-------------------------------------
Profitability:
- OCGN has a Return On Assets of -27.51%. This is better than the industry average of -35.66%.
- The profitability ratios for OCGN are negative, so there is not much use analyzing them.
- OCGN's Profit Margin of -13261.97% is worse than the rest of the industry. The industry average Profit Margin is -231.05%. 93% of the industry peers have a better Profit Margin.
- OCGN has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of OCGN.
-------------------------------------
Valuation:
The Price/Earnings Ratio is negative for OCGN. In the last year negative earnings were reported.
Also next year OCGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
With a price book ratio of 36.63, OCGN is valued rather expensively.
When comparing the price book ratio of OCGN to the average industry price book ratio of 4.95, OCGN is valued more expensive than its industry peers. 95% of the companies listed in the same industry are valued cheaper.
------------------------------------
Growth:
OCGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.87%, which is quite impressive.
When comparing the growth rate of the last years to the growth rate of the upcoming 2 years, we see that the growth is decreasing.
OCGN is expected to show a strong growth in Earnings Per Share. In the coming 2 years, the EPS will grow by 70.90% yearly.
------------------------------------
Health:
A Current Ratio of 4.78 indicates that OCGN has no problem at all paying its short term obligations.
OCGN has an Altman-Z score of 23.94. This indicates that OCGN is financially healthy and little risk of bankruptcy at the moment.
OCGN has one of the better Altman-Z scores in its industry. It is much better than the industry average of 3.73.
OCGN has a better score than 83% of its industry peers.
OCGN has a Current Ratio comparable to the industry average, which is at 6.14.
Compared to an average industry Debt to Equity Ratio of 0.01, OCGN is more dependent on financing than its industry peers.
OCGN has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of OCGN.
-------------------------------------
Taking everything into account, OCGN scores 3 out of 10 in our fundamental rating. OCGN was compared to 722 industry peers in the Drugs industry. The financial health of OCGN is medium. Also its profitability is quite bad. OCGN is quite expensive at the moment. It does show a decent growth rate.
Note: OCGN has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
-----------------------------------------
TP01 = 4,12000
TP02 = 4,91000
TP03 = 5,70000
TP04 = 6,49000
TP05 = 7,28000
------------------------------------------
Thank you for visiting my analysis. If you want to receive updates and follow the analysis of the most profitable stocks, please follow me and like the analysis, to receive notifications for all new .. Thank you and your follow-up motivates me to provide more ... I wish you success ♥♥♥
Technical Rating:
01- The long term trend is positive and the short term trend is neutral. The long term trend gets the benefit of the doubt for now.
02- OCGN is one of the better performing stocks in the Drugs industry, it outperforms 97% of 721 stocks in the same industry.
03- A new 52 week high is currently being made by OCGN, which is a very good signal! However, this is in line with the S&P500, which is also trading near new highs.
04- In the last month OCGN has a been trading in the 1.40 - 3.50 range, which is quite wide. It is currently trading near the high of this range.
05- OCGN has an average volume of 62182700. This is a good sign as it is always nice to have a liquid stock.
06- Looking at the yearly performance, OCGN did better than 98% of all other stocks. However, this relatively good performance is mostly due to a recent big move.
07- Considerably lower volume is observed in the last couple of days.
-------------------------------------
Statistics:
1 Month : -1.09%
3 Months :546.43%
6 Months : 229.09%
12 Months : 254.42%
-------------------------------------
Setup Analysis:
OCGN has an average technical rating and it also does not offer a high quality setup at the moment. Prices have been extended to the upside lately. For a nice entry it is better to wait for a consolidation.
-------------------------------------
Profitability:
- OCGN has a Return On Assets of -27.51%. This is better than the industry average of -35.66%.
- The profitability ratios for OCGN are negative, so there is not much use analyzing them.
- OCGN's Profit Margin of -13261.97% is worse than the rest of the industry. The industry average Profit Margin is -231.05%. 93% of the industry peers have a better Profit Margin.
- OCGN has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of OCGN.
-------------------------------------
Valuation:
The Price/Earnings Ratio is negative for OCGN. In the last year negative earnings were reported.
Also next year OCGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
With a price book ratio of 36.63, OCGN is valued rather expensively.
When comparing the price book ratio of OCGN to the average industry price book ratio of 4.95, OCGN is valued more expensive than its industry peers. 95% of the companies listed in the same industry are valued cheaper.
------------------------------------
Growth:
OCGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.87%, which is quite impressive.
When comparing the growth rate of the last years to the growth rate of the upcoming 2 years, we see that the growth is decreasing.
OCGN is expected to show a strong growth in Earnings Per Share. In the coming 2 years, the EPS will grow by 70.90% yearly.
------------------------------------
Health:
A Current Ratio of 4.78 indicates that OCGN has no problem at all paying its short term obligations.
OCGN has an Altman-Z score of 23.94. This indicates that OCGN is financially healthy and little risk of bankruptcy at the moment.
OCGN has one of the better Altman-Z scores in its industry. It is much better than the industry average of 3.73.
OCGN has a better score than 83% of its industry peers.
OCGN has a Current Ratio comparable to the industry average, which is at 6.14.
Compared to an average industry Debt to Equity Ratio of 0.01, OCGN is more dependent on financing than its industry peers.
OCGN has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of OCGN.
-------------------------------------
Taking everything into account, OCGN scores 3 out of 10 in our fundamental rating. OCGN was compared to 722 industry peers in the Drugs industry. The financial health of OCGN is medium. Also its profitability is quite bad. OCGN is quite expensive at the moment. It does show a decent growth rate.
Note: OCGN has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
-----------------------------------------
TP01 = 4,12000
TP02 = 4,91000
TP03 = 5,70000
TP04 = 6,49000
TP05 = 7,28000
------------------------------------------
Thank you for visiting my analysis. If you want to receive updates and follow the analysis of the most profitable stocks, please follow me and like the analysis, to receive notifications for all new .. Thank you and your follow-up motivates me to provide more ... I wish you success ♥♥♥
Trade closed: target reached:
TP01 = 4,12000
TP02 = 4,91000
TP03 = 5,70000
TP02 = 4,91000
TP03 = 5,70000
Trade closed: target reached:
TP04 = 6,49000
TP05 = 7,28000
TP05 = 7,28000